38:57

What happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)

32:37

AI and the Evolution of Market Access: What Comes Next? | ISPOR 2024 Panel Discussion

02:33

Market Access 4.0: Interview with Dr. Stefan Walzer | ISPOR 2024 Barcelona

30:27

How can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)

19:20

🔴 Best Practices in Dossier Creation with AI – in the context of rapid commercialization.

31:22

How might digitization change health care in Germany by 2035, Julian Molitor? (Repost)

31:31

How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Re...

34:07

What does environmental sustainability mean for Market Access, Gerdi Strydom?

38:31

What are the main obstacles in oncology market access, Ed Schoonveld? (Repost)

33:30

Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)

30:52

How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)

34:49

Summer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey Za...

34:27

What are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?

35:44

Large Language Models in Healthcare - Revolutionize dossier writing with AI

34:09

How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin K...

31:43

Optimize your Market Access Performance - Webinar by MARKET ACCESS 4.0

35:54

How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?

38:36

How Can AI Unlock the Potential of Market Access, Sandip Shah?

34:28

What Does the Future Hold for AI in Healthcare, Aleksey Zavgorodniy?

44:38

How to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jod...

31:08

How has virtual become reality in market access, Glib Kutepov?

31:28

What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?

33:06

Is Healthcare Just a Business in the US, Aymeric Chaupin?

32:02

A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?

33:08

Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?

34:25

Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?

34:11

Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)

33:15

How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?

33:41

What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)

33:53

The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff

34:06

Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.

32:00

How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?

31:00

AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?

36:26

Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?

30:49

How should market access and medical affairs work together, Dr. Mike Rosenblatt?

29:04

📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?

32:02

How does an optimized communication strategy look like, Dr. Arne Näveke?

34:26

How does the German evaluation committee work, Prof. Jürgen Wasem?

31:28

How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?

46:14

How do I get approved by the US FDA, Dr. Jamie Cross?

35:03

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

03:25

How do NEGOTIATIONS work in the VR rooms by MArS?

03:25

How do ORAL HEARINGS work in the VR rooms by MArS?

01:53

How do CONSULTATIONS work in the VR rooms by MArS?

30:36

How does market access work in Japan, Heather Wellam?

31:31

Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)

33:26

Is there a place for Real World Evidence in HTA, Dr. Karen Facey?

29:50

How can people get equal access to pharmaceuticals, Dr. Nina Lathia?

45:50

How to be successful in Canadian health care market access & pricing!

35:04

How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?

21:21

Is quality cancer care in Ukraine still possible, Yevgen Brovko?

32:34

What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?

33:13

EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira ...

36:42

The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!

38:28

What are the main obstacles in oncology market access, Ed Schoonveld?

38:39

Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?

39:25

The AMNOG process - how does it work from a legal perspective, Alexander Meier?

52:14

What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?

41:04

AMNOG Reform - will Germany remain the most attractive market for orphan drugs?

35:43

Why should Market Access Managers care about statistics, Alexander Schacht?